01.30.08
Roche
FY Revenues: $42.2 billion (+10%)
FY Earnings: $8.9 billion (+25%)
Comments: Pharmaceutical sales were up 10% to $32.7 billion. Earnings growth was driven by sales of cancer drugs, MabThera (+15%) to $4.9 billion, as well as Herceptin and Avastin. Rituxan sales reached $5.1 billion for the year. Tamiflu sales were down 19% to $1.9 billion. Pharmaceutical R&D expenses were $6.7 billion for the year (+15%).
FY Revenues: $42.2 billion (+10%)
FY Earnings: $8.9 billion (+25%)
Comments: Pharmaceutical sales were up 10% to $32.7 billion. Earnings growth was driven by sales of cancer drugs, MabThera (+15%) to $4.9 billion, as well as Herceptin and Avastin. Rituxan sales reached $5.1 billion for the year. Tamiflu sales were down 19% to $1.9 billion. Pharmaceutical R&D expenses were $6.7 billion for the year (+15%).